Fosaprepitant clinical trials
Fosaprepitant is named as an intervention in 3 current clinical trials in our China and South Korea registers. 1 is recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is The Affiliated People's Hospital of Ningbo University (1). The most-studied condition is Multiple Myeloma. The EU clinical trials register (CTIS) separately lists 1 authorised or ongoing trial.
Where Fosaprepitant is approved
All regulators →Of the three regulators tracked here, the first to approve Fosaprepitant was the EU, on 11 Jan 2008.
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
How Fosaprepitant works
All drug targets →- Neurokinin 1 receptor antagonist AntagonistTarget: TACR1 tachykinin receptor 1✓ In ChEMBL and the Guide to Pharmacology
- NauseaPhase 2/3
- Plasma cell myelomaPhase 1/2
- Brain injuryEarly phase 1
- Intracranial hypertensionEarly phase 1
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL1199324, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 7623, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Fosaprepitant
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- EUEuropean Union: IvemendEMA product information: package leaflet and summary of product characteristics in every EU language.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Reference identifiers for Fosaprepitant
- ChEMBL
- CHEMBL1199324
- DrugBank
- DB06717
- PubChem CID
- 135413538
- CAS number
- 172673-20-0
- FDA UNII
- 6L8OF9XRDC
- Wikidata
- Q5473324
- Wikipedia
- Fosaprepitant
Codes that identify this medicine in other databases, from Wikidata (CC0), matched by its ChEMBL ID. The ATC code is the WHO classification of what the medicine is used for.
Trials by status
Trials by phase
Clinical trials of Fosaprepitant
3 trials| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Prevention of Delayed CINV After Autologous Transplant: Olanzapine-Containing Regimen vs. Dexamethasone-Containing Regimen
NCT07413809 · ClinicalTrials.gov ↗ · Multiple Myeloma
|
Phase 3 | Recruiting | The Affiliated People's Hospital of Ningbo University | China |
|
Efficacy and Safety of Intravenous Versus Oral 5-HT3 Antagonists Combined With NK-1 Receptor Antagonists for the Prevention of CINV in Breast Cancer
NCT05841849 · ClinicalTrials.gov ↗ · Breast Cancer, Chemotherapy-induced Nausea and Vomiting
|
Phase 4 | Not yet open | Second Affiliated Hospital, Zhejiang University, School of Medicine | China |
|
Triple Therapy of Dexamethasone, Palonosetron, and Fosaprepitant As PONV Prevention
NCT05773950 · ClinicalTrials.gov ↗ · Postoperative Nausea and Vomiting, Gynecologic Surgical Procedures, Laparoscopy
|
Not applicable | By invitation | Samsung Medical Center | South Korea |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Fosaprepitant in the EU trials register (CTIS)
1 trialAuthorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Fosaprepitant. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Sponsor | Countries |
|---|---|---|---|---|
|
Postoperative recovery with the addition of long-acting NK1- and 5-HT3 receptor antagonists as prophylaxis for post-operative nausea and vomiting. A prospective, double-blind, randomized trial in laparoscopic surgery.
2025-522529-36-00 · CTIS ↗ · Anesthesia and Analgesia
|
Phase 3 | Authorised | Region Vaesternorrland, Umea University | Sweden |
Conditions studied with Fosaprepitant
6 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| The Affiliated People's Hospital of Ningbo University | 1 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | 1 |
| Samsung Medical Center | 1 |
By country register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 2 | 1 |
| Clinical trials in South Korea | 1 | 0 |
| EU register (CTIS) | 1 | — |
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
Related compounds
Questions about Fosaprepitant trials
How many clinical trials are testing Fosaprepitant?
3 current trials in our China and South Korea registers name Fosaprepitant as a drug or biological intervention, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.
Are Fosaprepitant trials recruiting patients?
Yes. 1 of the 3 trials is recruiting: 1 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Fosaprepitant clinical trials?
The Affiliated People's Hospital of Ningbo University (1), Second Affiliated Hospital, Zhejiang University, School of Medicine (1) and Samsung Medical Center (1). The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Fosaprepitant works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Fosaprepitant works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Fosaprepitant (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.